Key Highlights

  • FUM shares fell after a retail fundraise offering up to 75 million new shares at 0.2 pence, a discount of around 37.6% to the prior close.
  • The retail offer sits alongside a larger £1.6 million institutional fundraise, intended to extend the company's cash runway into February 2027.
  • Futura Medical confirmed it is pursuing a formal sale process under Rule 2.6 of the UK Takeover Code, covering Options from licensing to a full sale.
  • Eroxon, the company's topical erectile dysfunction gel, remains the key asset and most likely focus of any licensing or sale discussions.

A Discounted Fundraise to Extend the Runway

On 3 September 2026, Futura Medical announced a retail offer via the BookBuild platform, issuing up to 75 million new ordinary shares at 0.2 pence each to raise approximately £150,000 from existing UK shareholders, at a discount of around 37.6% to the prior closing price of 0.32 pence. The retail offer sits alongside a larger £1.6 million institutional fundraise made up of a firm placing, a conditional placing and a conditional subscription.

The retail offer closed on 4 September 2026, with a Shareholder vote to approve the fundraise scheduled for 23 September and admission of the new shares expected on 25 September 2026. Futura said the proceeds are intended to extend its cash runway into February 2027.

A Formal Sale Process Under Takeover Code Rules

Alongside the fundraise, Futura confirmed it is pursuing a formal sale process under Rule 2.6 of the UK Takeover Code, a mechanism that allows a company to explore strategic options — including the sale of individual assets, licensing arrangements, or a sale of the whole company — while managing the disclosure obligations that come with being formally 'in play'.

The extended cash runway to February 2027 gives the board time to run that process without the immediate pressure of a looming cash shortfall, but it also signals that the company sees no near-term standalone path to profitability without either a partner, an asset sale, or new ownership.

Dilution Meets Uncertainty

For existing shareholders, the fundraise brings meaningful dilution at a steep discount to the recent share price, a combination that often pressures small-cap shares even when the Capital raised is earmarked for a credible strategic purpose. Directors have participated in aspects of the wider fundraise, according to earlier disclosures, which some may read as a signal of continued management confidence even as the headline share price falls.

Eroxon itself — a fast-acting topical gel for erectile dysfunction sold over the counter in various markets, including the US — remains the company's key asset and the most likely focus of any licensing or sale discussions arising from the formal sale process. Whether that positioning translates into a licensing partner willing to pay a meaningful upfront sum, or a full takeover of the company, will likely determine whether the current dilution proves worthwhile for existing shareholders.

Conclusion

Futura Medical's share-price weakness reflects the twin pressures of near-term dilution and genuine uncertainty over the company's future ownership. The formal sale process could ultimately unlock real value from Eroxon through a licensing deal or a full takeover, but until that process delivers a concrete outcome, the shares are likely to stay sensitive to both the 23 September fundraise vote and any commentary on Eroxon's commercial performance.